Skip to Main Content

Try STAT+ TODAY

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Morning Rounds Newsletter

Pharma Olivia Goldhill

STAT Plus: Evangelist for legalizing MDMA therapy wrestles with his ideals as psychedelics go pharma

With MDMA nearing approval for PTSD, the Multidisciplinary Association for Psychedelic Studies faces the pressures of operating as a pharma firm.

Pharmalot Ed Silverman and Elaine Chen

STAT Plus: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight loss drugs

Pharmalot Ed Silverman

STAT Plus: Drug wholesaler owner indicted for alleged role in diverting Gilead and J&J HIV medicines

Pharma Elaine Chen

STAT Plus: After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market

Pharmalot Ed Silverman

STAT Plus: SEC charges former Pfizer statistician with insider trading over Paxlovid clinical trial results

All Coverage

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Drug-wholesaler owner indicted for alleged role in diverting HIV medicines; Catalent linked to Regeneron drug rejection

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA declines to approve higher dose version of Regeneron eye drug; FDA warns wholesaler over counterfeit HIV pills

advertisement

Health Angus Chen

STAT Plus: The cancer drug shortage isn’t new — and neither are the solutions: ‘It’s like Groundhog Day’

Pharmalot Ed Silverman

STAT Plus: FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines

Pharmalot Ed Silverman

STAT Plus: Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Lilly drug shows biggest weight loss yet in mid-stage trial; Biogen shareholders elect director’s romantic partner to the board

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Nearly half of U.S. adults would spend $100 a month for weight loss drugs; Pfizer scraps an obesity pill

Health Elaine Chen

STAT Plus: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal

Pharmalot Ed Silverman

STAT Plus: GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac

Health Angus Chen

STAT Plus: Using its Covid know-how, Color Health aims to make cancer screenings convenient

Politics Rachel Cohrs

STAT Plus: The strategy behind the pharmaceutical industry’s flurry of lawsuits challenging drug pricing reform

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Europe regulator raised safety signal on Novo drugs; U.S. seeks new trial over royalties on Gilead HIV prevention pills

Pharmalot Ed Silverman

STAT Plus: U.S. seeks a new trial over royalties on Gilead HIV prevention pills

Politics John Wilkerson

STAT Plus: Drug middlemen catch flak at another congressional hearing

Politics Sarah Owermohle

STAT Plus: Sen. Grassley calls on GOP leaders to rally support for PBM reforms

Video Chat Ed Silverman and Rachel Cohrs

STAT Virtual Event: The Next Frontier of Drug Pricing Reform

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Novo Nordisk sues spas, clinics over compounded Wegovy; top lobbyist leaves PhRMA

Pharmalot Ed Silverman

STAT Plus: Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Opaque conflicts permeate prescription drug benefits; Sanofi prevails in Zantac arbitration

A STAT Investigation Bob Herman

STAT Plus: ‘It’s beyond unethical’: Opaque conflicts of interest permeate prescription drug benefits

Politics Rachel Cohrs

STAT Plus: How drug pricing reforms are affecting Bayer’s investments

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Bristol Myers sues HHS over Medicare drug negotiations; Lilly reports new shortages of Mounjaro diabetes drug